News coverage about Globus Medical (NYSE:GMED) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Globus Medical earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 46.2463138140423 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Medical Equipment Stock Performance Review — Amedica, Steris, Smith & Nephew, and Globus Medical (medindia.net)
- Globus Medical : Medical Equipment Stock Performance Review — Amedica, Steris, Smith & Nephew, and Globus Medical (4-traders.com)
- Globus Medical, Inc. (GMED) Downgraded by BidaskClub (americanbankingnews.com)
- Globus Medical (GMED) Reports First Spine Surgeries Using ExcelsiusGPS (streetinsider.com)
- Globus Medical, Inc. (GMED) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
GMED has been the topic of a number of recent research reports. Zacks Investment Research lowered Globus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. BidaskClub lowered Globus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Oppenheimer Holdings, Inc. set a $35.00 price objective on Globus Medical and gave the stock a “hold” rating in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the stock. Globus Medical presently has a consensus rating of “Hold” and an average target price of $30.71.
Globus Medical (NYSE GMED) opened at 29.00 on Tuesday. Globus Medical has a 52 week low of $19.25 and a 52 week high of $34.03. The stock has a 50 day moving average price of $29.91 and a 200 day moving average price of $30.89. The firm has a market cap of $2.79 billion, a price-to-earnings ratio of 26.13 and a beta of 0.56.
Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. The business had revenue of $152.39 million during the quarter, compared to the consensus estimate of $150.94 million. Globus Medical had a return on equity of 13.99% and a net margin of 18.12%. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.29 earnings per share. Equities research analysts expect that Globus Medical will post $1.26 EPS for the current year.
In related news, insider A Brett Murphy sold 15,000 shares of Globus Medical stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $29.99, for a total value of $449,850.00. Following the transaction, the insider now owns 101,217 shares in the company, valued at $3,035,497.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 28.21% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2017/10/17/globus-medical-gmed-receiving-somewhat-positive-news-coverage-accern-reports.html.
About Globus Medical
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.